EOM Pharmaceutical Holdings Inc. (IMUC)

[sts66]

No, Q1/13 is way too soon for results.....ok, found the PR, says (maybe) late 2013, one of the reasons I'm in no hurry to get any stock yet:

ImmunoCellular expects that the trial’s data safety monitoring committee will conduct an interim safety analysis when 32 events (patients deaths) have occurred, which is anticipated in the first quarter of 2013. Depending on the progress of the trial, final safety and efficacy results from the Phase II trial could be available late in the second half of 2013.